Intended for healthcare professionals

Letters Future of flu vaccines

Expediting clinical trials in a pandemic

BMJ 2009; 339 doi: (Published 10 November 2009) Cite this as: BMJ 2009;339:b4652
  1. Andrew J Pollard, professor of paediatric infection and immunity1,
  2. Amanda Reiner1,
  3. Tessa John1,
  4. Elizabeth Sheasby2,
  5. Matthew Snape1,
  6. Saul Faust3,
  7. Andrew Collinson4,
  8. Adam Finn5,
  9. Paul T Heath6,
  10. Elizabeth Miller2
  1. 1Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford OX3 9DU
  2. 2Immunisation Department, Centre for Infection, Health Protection Agency, Colindale
  3. 3University of Southampton Wellcome Trust Clinical Research Facility, Southampton
  4. 4Royal Devon and Exeter NHS Foundation Trust, Exeter
  5. 5Bristol Children’s Vaccine Centre, University of Bristol, Bristol
  6. 6St George’s Vaccine Institute, University of London, London
  1. andrew.pollard{at}

    In response to the urgent need for paediatric data comparing the two new variant A/H1N1 vaccines in the UK before the onset of a second wave of flu,1 and a call for proposals related to new variant A/H1N1 by the National Institute for Health Research (NIHR),2 we designed a clinical trial of immunogenicity and tolerability in children aged 6 months-12 years. We submitted a collaborative funding application to NIHR on 24 July 2009, receiving an award letter …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription